ELI LILLY Aktie

 

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story....

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants....

How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight Authored by Paul D. Thacker via The DisInformation Chronicle, New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine injury clinic based on a leaked statement by Jack Leslie, a senior advisor to the PR firm Weber Shandwick which represents most major vaccine manufacturers. I'm not joking. This is the journalism I get for my paid subscription to the New York Times. Like most senior executives at the global PR firm Weber Shandwick, Jack Leslie makes buckets of money helping corporations sell themselves and their products to the American public. In the last handful of years, Weber Shandwick's clients have included the bulk of the global vaccine giants including Pfizer, Moderna, GSK, Sanofi, Novartis, and Eli Lilly. But when he's not raking in oodles of cash repping corporate America, Leslie also takes on some unpaid healthcare...

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

New York (www.aktiencheck.de) - Eli Lilly-Aktienanalyse von Goldman Sachs: Die Analysten von Goldman Sachs erhöhen das Kursziel für die Aktie von Eli Lilly and Company (ISIN: US5324571083, WKN: 858560, Ticker-Symbol: LLY, NYSE-Symbol: LLY) von 1.371 USD auf 1.413 USD und bestätigen ihr "buy"-Rating. [mehr]...

Novo Nordisk setzt große Hoffnungen auf CagriSema. Der experimentelle Wirkstoff gilt als Nachfolger des Bestsellers Wegovy. Damit könnte der dänische Konzern im schnell wachsenden Markt für Gewichtsreduktion Boden gegenüber Rivale Eli Lilly zurückgewinnen....

The pharmaceutical industry is relatively less correlated to the rest of the economy, and that's a diversification benefit for investors....

Wall Street's primary indices saw an uptick, primarily driven by healthcare stocks reaching all-time highs amid falling oil prices. Investors are scrutinizing corporate earnings, with increasing worries about artificial intelligence expenditure impacting market stability. Significant advances from companies like Eli Lilly and Equifax boosted overall market performance. Nevertheless, General Motors and Steel Dynamics struggled with elevated costs and missed profit expectations....

A European regulatory endorsement for an oral obesity pill is lifting Eli Lilly (NYSE:LLY) stock ahead of the rest of the drug group. Eli Lilly stock is up 4% to $1,295.58 in afternoon trading, with the gain building on a recommendation that brings Foundayo closer to European patients. Foundayo now stands one regulatory step from […]...

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

On Oct. 20, 2026, major U.S. indexes gained as falling oil prices boosted blue chips and semiconductors edged upwards....

Eli Lilly just posted 47.7% revenue growth and its weight-loss drugs are reshaping global healthcare, but whether that momentum turns a four-year investment into a windfall or a disappointment depends on factors most investors overlook....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Am Dienstag präsentieren sich zahlreiche Pharma-Aktien in einer starken Verfassung. Im S&P 500 gehört das Papier von Eli Lilly zu den absoluten Top-Gewinnern und nimmt das bisherige Rekordhoch aus dem Markt. Zur Stunde gewinnt der Pharma-Wert rund fünf Prozent an Wert und rangiert damit erstmals um die Marke von 1....

Für internationale Konzerne ist Deutschland seit Jahren immer weniger attraktiv. Sie meiden den Standort ganz oder halbieren geplante Investitionen, wie etwa der Pharmakonzern Eli Lilly in Alzey. Die Folgen sind gravierend. Von Axel John....

METIS TECHBIO-P (07666.HK) announced a strategic partnership with Eli Lilly and Company (LLY.US) on novel lipid nanoparticle (LNP) delivery solutions. Under the agreement terms, METIS TECHBIO-P will receive an upfront payment exceeding USD10 million and will be eligible to receive development, regulatory and commercial milestone......

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -1.33% move from the previous day....

Eli Lilly just crushed earnings again and sits within striking distance of its all-time high, but a looming price war with Novo Nordisk and a dangerously concentrated revenue base raise real questions about how long the momentum holds....

Eli Lilly is growing quickly, lowering realized prices, and building its next wave of drugs. Here's what the numbers say about margins, valuation, and the catalysts that matter next....